Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Gynecologic 2Genitourinary 2Thoracic 1Other hematologic neoplasm 1Endocrine 1CNS 1

Conditions

Leukemia 1

Interventions

venetoclax 75Cyclophosphamide 68Cytarabine 59fludarabine 49Azacitidine 44Specimen Handling 36fludarabine phosphate 35Rituximab 34Biopsy 30Methotrexate 28ibrutinib 27Daunorubicin 25Dexamethasone 24Vincristine 23obinutuzumab 21Etoposide 21Decitabine 21acalabrutinib 19Tacrolimus 19Dasatinib 19blinatumomab 18Melphalan 18Prednisone 16Mycophenolic Acid 16Granulocyte Colony-Stimulating Factor 16Busulfan 16Whole-Body Irradiation 15Doxorubicin 15Injections 14pegaspargase 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × talazoparib × Other hematologic neoplasm × Clear all
NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
13 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡